| Pharmaceutical Information |
| Drug Name |
Nafarelin |
| Drug ID |
BADD_D01513 |
| Description |
Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis. |
| Indications and Usage |
For treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis. |
| Marketing Status |
approved |
| ATC Code |
H01CA02 |
| DrugBank ID |
DB00666
|
| KEGG ID |
D08241
|
| MeSH ID |
D017274
|
| PubChem ID |
25077405
|
| TTD Drug ID |
D08WYM
|
| NDC Product Code |
Not Available |
| UNII |
1X0094V6JV
|
| Synonyms |
Nafarelin | Synarel | RS-94991-298 | RS 94991 298 | RS94991298 | Nafarelin Acetate | Nafarelin Acetate, Hydrate | Nafarelin Monoacetate |
|
| Chemical Information |
| Molecular Formula |
C66H83N17O13 |
| CAS Registry Number |
76932-56-4 |
| SMILES |
CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CC3=CC=CC=C3C=C
2)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=C
N7)NC(=O)C8CCC(=O)N8 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
